Table 3.
Demographic And Clinical Data Of The DR And Non-DR Groups
| Variable | DR | Non-DR | P value |
|---|---|---|---|
| Sex | 0.248a | ||
| Male | 4(20.0%) | 26(33.3%) | |
| Female | 16(80.0%) | 52(66.7%) | |
| Duration of pain, (years), mean±SD | 6.7±5.2 | 6.0±5.5 | 0.831b |
| Age (years), | 0.690a | ||
| <60 | 11(55.0%) | 39(50.0%) | |
| ≥60 | 9(45.0%) | 39(50.0%) | |
| Side | 0.748a | ||
| Left | 9(45.0%) | 32(41.0%) | |
| Right | 11(55.0%) | 46(59.0%) | |
| Distribution | 0.727a | ||
| V1 | 0(0%) | 0(0.0%) | |
| V2 | 9(45.0%) | 24(30.8%) | |
| V3 | 3(15.0%) | 9(11.5%) | |
| V1+V2 | 2(10.0%) | 12(15.4%) | |
| V2+V3 | 5(25.0%) | 27(34.6%) | |
| V1+V2+V3 | 1(5%) | 6(7.7%) | |
| Carbamazepine | 0.522a | ||
| Effective | 11(55.0%) | 49(62.8%) | |
| Invalid | 9(45.0%) | 29(37.2%) | |
| Type | 0.301a | ||
| Typical | 20(100%) | 74(94.9%) | |
| Atypical | 0(0%) | 4(5.1%) | |
| Destructive treatment | 0.846a | ||
| Yes | 2(10.0%) | 9(11.5%) | |
| No | 18(80.0%) | 69(88.5%) |
Notes: aP value: Pearson’s χ2 test or Fisher’s exact test; bP value: t-test.